LEO Pharma's SPEVIGO Data Bolsters Long-Term GPP Treatment Outlook
Event summary
- LEO Pharma presented long-term data from the EFFISAYIL ON study at the 2026 AAD Annual Meeting.
- The study showed a reduction in GPP flares from 2.0 per year to 0.13 per year with SPEVIGO treatment.
- 74.6% of patients on SPEVIGO for three or more years experienced no flares.
- Intravenous SPEVIGO demonstrated effectiveness in treating flares, with 50% achieving clear pustulation at Week 1.
The big picture
LEO Pharma's SPEVIGO represents a significant advancement in treating GPP, a rare and debilitating condition with limited treatment options. The long-term data reinforces the drug's efficacy but also highlights the complexities of managing a chronic, unpredictable disease. The company's commitment to ongoing data generation and the dual IV/SC approach underscores the need for a comprehensive treatment strategy in this niche market.
What we're watching
- Market Adoption
- The sustained adoption of SPEVIGO will depend on physician comfort with the IV flare treatment protocol and patient adherence to the subcutaneous maintenance regimen, particularly given the reported adverse event profile.
- Competitive Landscape
- Emerging therapies targeting the IL-36 pathway could erode SPEVIGO’s market share, necessitating continued innovation and data generation to maintain its clinical advantage.
- Regulatory Scrutiny
- The reported serious adverse events, particularly GBS, will likely draw increased regulatory scrutiny and require proactive risk mitigation strategies from LEO Pharma.
Related topics